Preview

Артериальная гипертензия

Расширенный поиск

Ремоделирование сердечно сосудистой системы при тиреотоксикозе, его влияние на жизненный прогноз

https://doi.org/10.18705/1607-419X-2007-13-1-14-21

Полный текст:

Аннотация

В настоящем обзоре представлены современные данные о влиянии тиреотоксикоза на геометрию сердца, сердечно-сосудистый и жизненный прогноз, современные представления о механизмах ремоделирования миокарда при тиреотоксикозе и его характере, обратимости этих изменений. В обзоре также представлены некоторые сведения о возможности медикаментозной коррекции ремоделирования миокарда при тиреотоксикозе, мерах профилактики.

Об авторе

А. Ю. Бабенко
Кафедра факультетской терапии СПбГМУ им. акад. И.П. Павлова
Россия


Список литературы

1. Klein I. Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol. Endocrinology 1988 123 203-210

2.

3. Mintz G., Pizzarello R., Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab. 1991;73:146-50

4.

5. Proskey A.J., Saksena F., Towne W.D. 1971, Myocardial infarction associated with thyrotoxicosis. Chest 72:109-113

6.

7. Ortmann C., Pfeiffer H., Du Chesne A., Brinkmann В. Inflammation of the cardiac conduction system in a case of hyperthyroidism. Int J Legal Med 1999 112:271-274

8.

9. Reinwein D., Benker G., Lazarus J.H. and Alexander W.D. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. Journal of Clinical Endocrinology & Metabolism, Vol 76, 1516-1521, 1993

10.

11. Abraham P., Avenell A., Park C.M., Watson W.A. and Bevan J.S. A systematic review of drug therapy for Graves' hyperthyroidism. European Journal of Endocrinology, Vol 153, Issue 4, 489-498, 2005

12.

13. Bradley E.L. III, DiGirolamo M., Tarcan Y.,1980, Modified subtotal thyroidectomy in the management of Graves' disease. Surgery. 1980;87:623-9.

14.

15. Franklyn J.A.,Daykin J., Drolc Z., Farmer M., Sheppard M.C. Long-term follow-up of treatment of thyrotoxicosis by three different methods.Clin Endocrinol (Oxf). 1991 Jan;34(l):71-6.

16.

17. Sugrue D., McEvoy M., Feely J., Drury M.I. Hyperthyroidism in the land of Graves: results of treatment by surgery, radioiodine and carbimazole in 837 cases. Q J Med 1980;193:51-61.

18.

19. Cusick E..L, Krukowski Z.H., Matheson N.A., Outcome of surgery for Graves' disease reexamined. Br J Surg 1987;74:780-3.

20.

21. Sawin C.T., Geller A., Wolf P.A., Belanger A. J., Baker E., Bacharach P., Wilson P., Benjamin E.J., and D'Agostino R.B. Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons NEJM V 331:1249-1252, Nov, N19

22.

23. Biondi B., Palmieri E., Lombardi G., Fazio S. 2002 Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 137:904-914

24.

25. Ojamaa K., Sabet A., Klein I., Kenessey A., Shenoy R. Regulation of rat cardiac Kvl.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 1999 140 3170-3176

26.

27. Osman F., Gammage M. D., Sheppard M. C. and Franklyn J. A. Cardiac Dysrhythmias and Thyroid Dysfunction - The Hidden Menace? The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 3 963-967

28.

29. Franklyn J.A., Maisonneuve P., Sheppard M.C., Betteridge J., Boyle P., Mortality after the Treatment of Hyperthyroidism with Radioactive Iodine NEJM V 338:712-718, March 12, 1998, N 11

30.

31. Franklyn J.A., Maisonneuve P., Sheppard M.C. Thyroid Function and Mortality in Patients Treated for Hyperthyroidism JAMA. 2005;294 №1, c..71-80

32.

33. Ladenson P.W. 1993 Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab 77:332-333 (Editorial)

34.

35. Parker J.L.W., Lawson D.H. 1973, Death from thyrotoxicosis. Lancet 2:894-896

36.

37. Flynn R.W.V., MacDonald T.M., Jung R.T., Morris A.D. and Leese G. P. Mortality and Vascular Outcomes in Patients Treated for Thyroid Dysfunction J. of Clinical Endocrinology & Metabolism, Vol. 91, No. 6 2159-2164, 2006

38.

39. Hoffman, D.A., McConahey W.M., Diamondand E.L.,Kurland L.T. Mortality in women treated for hyperthyroidism. Am J Epidemiol 1982 ;115:243-54.

40.

41. Parle J., Maisonneuve P., Sheppard M., Boyle P., Franklyn J. 2001 A single low serum thyrotrophin (TSH) concentration predicts increased all-cause and cardiovascular mortality in older persons in the community: a 10-year cohort study. Lancet 358:861-865

42.

43. Cappola, A.R. Fried L.P., Arnold A.M.,.Danese M.D., Kuller L.H., Burke G.L., Tracy R.P., Ladenson P.W., Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults. JAMA. 2006;295:1033-1041

44.

45. Sawin C., Geller A., Wolf P., Belanger A.J., Baker E.,Bacharach P., Wilson P.W., Benjamin E.J., D'Agostino R.B. 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249-1252

46.

47. Iwasaki T., Naka M., Hiramatsu K., Yamada T., Niwa A., Aizawa T., Murakami M., Ishihara M., Miyahara Y. Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves' disease. Cardiology. 1989;76(l):10-7

48.

49. Nakazawa H.K., Sakurai K., Hamada N., Nakazawa H.K., Sakurai K., Hamada N., Momotani N., Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med. 1982;72:903-6

50.

51. Dunn M., Alexander J., de Silva R., Hildner F. Antithrombotic therapy in atrial fibrillation. Chest. 1989;95(2 Suppl):118S-127S.

52.

53. Presti C, Hart R 1989 Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 117:976-977

54.

55. Donnini D., Ambesi-Impiombato F.S., Curcio F. Thyrotropin stimulates production of procoagulant and vasodilative factors in human aortic endothelial cells. Thyroid. 2003 Jun;13(6):517-21.

56.

57. Burggraaf J., Lalezari S., Emeis J.J., Vischer U.M., de Meyer P.H., Pijl H., Cohen A.F. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol Thyroid. 2001 Feb;ll(2):153-60. .

58.

59. Dцrr M., Robinson D.M., Wallaschofski H., Schwahn C., John U., Felix S.B. and Viilzke H. Low Serum Thyrotropin Is Associated with High Plasma Fibrinogen 2006 The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 2 530-534

60.

61. Haissaguerre M., Jais P., Shah D., Takahashi A., Hocini M., Quiniou G., Garrigue S., Le Mouroux A., Le Metayer P., Clementy J. 1998 Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666

62.

63. Von Olshausen K., Bischoff S., Kahaly G., Mohr-Kahaly S., Erbel R., Beyer J., Meyer J. 1989 Cardiac arrhythmias and heart rate in hyperthyroidism. Am J Cardiol 63:930-933

64.

65. Osman F., Daykin J., Sheppard M., FranklynJ, Gammage M 2000 Cardiac rhythm abnormalities in thyrotoxicosis-the explanation for excess vascular mortality. J Endocrinol 164:P321

66.

67. Golf S., Lovstad R., Hansson V. 1985 Beta-adrenoceptor density and relative number of beta-adrenoceptor subtypes in biopsies from human right atrial, left ventricular, and right ventricular myocard. Cardiovasc Res 19:636-641

68.

69. Zhao X.-S., Gallardo T. D., Lin L., Schageman J. J., and Shohet R. V. Transcriptional mapping and genomic analysis of the cardiac atria and ventricles Physiol Genomics, December 26, 2002; 12(1): 53-60.

70.

71. Stiles G., Taylor S., Lefkowitz R. 1983 cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci 33:467-473

72.

73. Dцrr M., Wolff B., Robinson D. M., John U., Lьdemann J., Meng W.,.Felix S .В and Viilzke H. The Association of Thyroid Function with Cardiac Mass and Left Ventricular Hypertrophy The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 2 673-677

74.

75. Kapitola J. & Vilimovskб D., 1981, Inhibition of the early circulatory effects of triiodothyronine in rats by propranolol. Physiol Bohemoslov 30:347-351

76.

77. Levey G.S. & Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. American Journal of Medicine 1990 88 642-646

78.

79. Levey G.S. Catecholamine sensitivity, thyroid hormone and the heart. American Journal of Medicine 1971 50 413-420

80.

81. Haro J.M., Sabio J.M. & Vargas F. Renal and cardiac beta-adrenoceptors in thyroxine-treated rats. Journal of Endocrinological Investigation 1992 15 605-608

82.

83. Williams L.T., Lefkowitz R.J., Watanabe A.M., Hathaway D.R. & Besch H.R.Jr. Thyroid hormone regulation of B-adrenergic receptor number. Journal of Biological Chemistry 1977 252 2787-2789

84.

85. Polikar R., Kennedy B., Ziegler M., O'Connor T., Smith J. & Nicod P. Plasma norepinephrine kinetics, dopamine-B-hydroxylase and chromogranin A in hypothyroid patients before and following replacement therapy. Journal of Clinical Endocrinology and Metabolism 1990 70 277-281

86.

87. Bilezikian J.P. & Loeb J.N. 1982 Mechanisms of altered beta-adrenergic responsiveness in the hyperthyroid and hypothyroid turkey erythrocyte. Life Science 1982 30 663-674

88.

89. Klein I., Ojamaa К. Thyroid Hormone and the Cardiovascular System NEJM 2001, V 344:501-509, фев 15, N 7

90.

91. Ching G.W., Franklyn J.A., Stallard T.J., Daykin J., Sheppard M.C., Gammage M.D. 1996 Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart 75:363-368

92.

93. Kahaly G.J. and Dillmann W.H., Thyroid Hormone Action in the Heart. Endocr. Rev., August 1, 2005; 26(5): 704-728

94.

95. Basset A., Blanc J., Messas E., Hagege A., Elghozi J.L., 2001, Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study. J Cardiovasc Pharmacol. 2001 Feb;37(2): 163-72

96.

97. Hu L.W., Benvenuti L.A., Liberti E.A., Carneiro-Ramos M.S., and Barreto-Chaves M.L.M. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2003; 285(6): R1473-1480.

98.

99. Vargas F., Moreno J.M., Rodriguez-Gomez I., Wangensteen R., Osuna A., Alvarez-Guerra M., and Garcia-Estan J. Vascular and renal function in experimental thyroid disorders Eur. J. Endocrinol., February 1, 2006; 154(2): 197-212.

100.

101. Marchant C., Brown L. & Sernia C. Renin-angiotensin system in thyroid dysfunction in rats. Journal of Cardiovascular Pharmacology 1993 22 449-455

102.

103. Ganong .WF.,Thyroid hormones and renin secretion. Life Science 1982 30 577-584

104.

105. Jimiinez E., Montiel M., Narv6ez J.A. & Morel M. Effects of hyper-and hypothyroidism on the basal levels of angiotensin I and kinetic parameters of renin angiotensin system in male rats. Revista Espanola de Fisiologia 1982 38 149-154

106.

107. Lear W., Ruzicka M. and Leenen F.H. ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 273: H641-H646, 1997

108.

109. Churchill P.C., Churchill M.C. & McDonald F.D., Evidence that B-adrenoceptor activation mediates isoproterenol-stimulated renin secretion in the rat. Endocrinology 1983 113 687-692

110.

111. Atlas S.A., Sealey J.E., Larag J.H. & Moon С. Plasma renin and 'prorenin' in essential hypertension during sodium depletion, beta-blockade and reduced arterial pressure. Lancet 1977 785-789

112.

113. Kobori H., Ichihara A., Suzuki H., Miyashita Y., Hayashi M., and Saruta T. Thyroid hormone stimulates renin synthesis in rats without involving the sympathetic nervous system. Am J Physiol Endocrinol Metab 272: E227-E232, 1997

114.

115. GarcHa-Estan J., Atucha N., Quesada T. & Vargas F. Involvement of the reninangiotensin system in the reduced pressure-natriuresis response of hyperthyroid rats. American Journal of Physiology 1995 268 E897-E901

116.

117. Gаrсна del Rho C., Moreno M.R.R., Osuna A., Luna J.D., GarcHa-Estan J. & Vargas F. Role of the reninangiotensin system in the development of thyroxine-induced hypertension. European Journal of Endocrinology 1997

118.

119. Asahi T., Shimabukuro M., Oshiro Y., Yoshida H., Takasu N., Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats Thyroid. 2001 Nov;ll(ll):1009-15.

120.

121. Kobori H., Ichihara A., Miyashita Y., Hayashi M. and Saruta T. Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy Journal of Endocrinology, 1999, Vol 160, Issue 1, 43-47

122.


Для цитирования:


Бабенко А.Ю. Ремоделирование сердечно сосудистой системы при тиреотоксикозе, его влияние на жизненный прогноз. Артериальная гипертензия. 2007;13(1):14-21. https://doi.org/10.18705/1607-419X-2007-13-1-14-21

For citation:


Babenko A.Y. Cardiovascular remodeling in thyrotoxicosis and its prognostic implication. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(1):14-21. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-1-14-21

Просмотров: 80


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)